181 related articles for article (PubMed ID: 24336076)
1. The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck cancer.
Roh JL; Kim EH; Park HB; Park JY
Cell Death Dis; 2013 Dec; 4(12):e956. PubMed ID: 24336076
[TBL] [Abstract][Full Text] [Related]
2. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.
Vaseva AV; Yallowitz AR; Marchenko ND; Xu S; Moll UM
Cell Death Dis; 2011 May; 2(5):e156. PubMed ID: 21562588
[TBL] [Abstract][Full Text] [Related]
3. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer.
Roh JL; Park JY; Kim EH
Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507
[TBL] [Abstract][Full Text] [Related]
4. The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells.
Hirakawa H; Fujisawa H; Masaoka A; Noguchi M; Hirayama R; Takahashi M; Fujimori A; Okayasu R
Cancer Med; 2015 Mar; 4(3):426-36. PubMed ID: 25582113
[TBL] [Abstract][Full Text] [Related]
5. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P
J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678
[TBL] [Abstract][Full Text] [Related]
6. p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Fujii Y; Kato T; Kubota N; Fujimori A; Niwa O; Okayasu R
Oncol Rep; 2010 Jan; 23(1):199-203. PubMed ID: 19956882
[TBL] [Abstract][Full Text] [Related]
7. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
[TBL] [Abstract][Full Text] [Related]
8. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
Nam S; Kim H; Hong D; Park JB; Kim SJ
Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
[TBL] [Abstract][Full Text] [Related]
9. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
Tse AN; Sheikh TN; Alan H; Chou TC; Schwartz GK
Mol Pharmacol; 2009 Jan; 75(1):124-33. PubMed ID: 18820127
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
Chung YL; Troy H; Banerji U; Jackson LE; Walton MI; Stubbs M; Griffiths JR; Judson IR; Leach MO; Workman P; Ronen SM
J Natl Cancer Inst; 2003 Nov; 95(21):1624-33. PubMed ID: 14600095
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
12. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
Lombardi R; Sonego M; Pucci B; Addi L; Iannelli F; Capone F; Alfano L; Roca MS; Milone MR; Moccia T; Costa A; Di Gennaro E; Bruzzese F; Baldassarre G; Budillon A
Mol Oncol; 2021 Apr; 15(4):1005-1023. PubMed ID: 33331136
[TBL] [Abstract][Full Text] [Related]
13. Hsp90 inhibitors promote p53-dependent apoptosis through PUMA and Bax.
He K; Zheng X; Zhang L; Yu J
Mol Cancer Ther; 2013 Nov; 12(11):2559-68. PubMed ID: 23966620
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis.
Machida H; Nakajima S; Shikano N; Nishio J; Okada S; Asayama M; Shirai M; Kubota N
Cancer Sci; 2005 Dec; 96(12):911-7. PubMed ID: 16367912
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells.
Myung SJ; Yoon JH; Kim BH; Lee JH; Jung EU; Lee HS
J Pharmacol Exp Ther; 2009 Jul; 330(1):276-82. PubMed ID: 19329756
[TBL] [Abstract][Full Text] [Related]
17. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer.
Roh JL; Kim EH; Park JY; Kim JW; Kwon M; Lee BH
Oncotarget; 2014 Oct; 5(19):9227-38. PubMed ID: 25193861
[TBL] [Abstract][Full Text] [Related]
18. Targeting GRP75 improves HSP90 inhibitor efficacy by enhancing p53-mediated apoptosis in hepatocellular carcinoma.
Guo W; Yan L; Yang L; Liu X; E Q; Gao P; Ye X; Liu W; Zuo J
PLoS One; 2014; 9(1):e85766. PubMed ID: 24465691
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein 90 inhibitor attenuates renal fibrosis through degradation of transforming growth factor-β type II receptor.
Noh H; Kim HJ; Yu MR; Kim WY; Kim J; Ryu JH; Kwon SH; Jeon JS; Han DC; Ziyadeh F
Lab Invest; 2012 Nov; 92(11):1583-96. PubMed ID: 22964853
[TBL] [Abstract][Full Text] [Related]
20. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
